When China Health Resources (CHRI) decided to put the bulk of their energy into the development and marketing of Dahurian Angelica Root (which has affectionately become known as “DAR”) It raised some eyebrows. It’s not that often when a very promising company puts most of their eggs in one basket, but yet this is exactly what CHRI did. At first glance this may seem a bit foolhearty, but time has shown us that this was one of the single best moves that a traditional herbal medicine company could make.
DAR has become one of the fastest growing and most demanded herbal remedies in all of China, and in significant portions of India. It’s been shown to help, and even cure in some instances, everything from gum disease, toothache, stomach ache, to blood pressure, migraines and even certain cancers. Yes it’s that important and the Chinese populace had been demanding more and better forms of the herb for years.
Through its subsidiary, Suining Yinfa DAR Industrial Co., Ltd, – China Health Resource, Inc. (CHRI) is committed to developing traditional Chinese herbal medicines. Yet just producing and marketing a high quality DAR product wasn’t enough for China Health, they stepped it up to a whole new level. Working with regulators of the European Union, they helped create a unique category of ranking for Dahurian Angelica Root, and it’s called aptly enough, Good Agricultural Practice or GAP.
GAP takes into account some overriding parameters set forth by the Food and Agriculture Organization of the United Nations. It monitors and measures not only the quality of the product itself (good agricultural product ranking) but of the soil standards, erosion standards, fertilization standards, etc. In layman’s terms, getting a foodstuff certified as “GAP” is almost the equivalent of getting an FDA approval here in the United States.
When China Health helped develop the European Union’s classification for DAR, and was subsequently granted their GAP certificates in the EU, the State regulatory agency in China took note, and accepted it as the benchmark certificate there also. In one fell swoop, CHRI became the defacto “gold standard” of DAR production, and marketing. This is why China Health was indeed willing to put so many eggs in one basket.
Not only did they enjoy the demand of a thousand year culture of herbal remedies in mainland China and the outlier areas such as India, but they also helped set the gold standard for what DAR should be, and then produced their herb to that exacting standard. Talk about a coup!
Attaining state sponsored recognition for an herbal remedy, in which you helped set the parameters of quality, is a mighty accomplishment and one for which we feel CHRI will be rewarded. Here in the states, if you receive FDA approval for a drug, foodstuff, supplement, etc, you can almost guarantee yourself some instant success, as the ranking provides instant credibility. The result in China and the European Union can be expected to be the same.
China health has set some very high standards, which it is achieving daily. By laying the foundation for what DAR production should be in this day and age, it has proven to the world that it is the world class, state of the art producer of DAR, and will indeed reap the rewards of such sigh recognition.
Investors willing to delve into the area of homeopathic and/or herbal medicine and reap the benefits of a 30 billion dollar a year and growing business should take a serious look at CHRI. The GAP ranking they have helped set the standards for, and the certificates they’ve received, can be closely compared to attaining the FDA approval here in the States, and most would agree that the credibility that it brings to the table is usually rewarded in the investment return. It demands a close look.
Let us hear your thoughts: China Health Resource, Inc. Message Board